The Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome
A Real-world Study to Evaluate the Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome
Sponsor: Capital Institute of Pediatrics, China
Listed as NCT03332420, this observational or N/A phase trial focuses on Nephrotic Syndrome and remains completed. Sponsored by Capital Institute of Pediatrics, China, it has been updated 13 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Sep 2022 — Jan 2023 [monthly]
Completed
-
Jun 2022 — Sep 2022 [monthly]
Completed
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Mar 2022 — Jun 2022 [monthly]
Active Not Recruiting
-
Sep 2021 — Mar 2022 [monthly]
Active Not Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Apr 2020 — Jan 2021 [monthly]
Recruiting
-
Oct 2019 — Apr 2020 [monthly]
Recruiting
-
Jun 2018 — Oct 2019 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Dec 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Capital Institute of Pediatrics, China
- Qidong Gaitianli Medicines Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changchun, China , Chengdu, China , Chongqing, China , Harbin, China , Nanchang, China , Nanjing, China , Suzhou, China , Taiyuan, China , Tianjin, China and 6 more locations